Skip to content

Lariva Business

Lariva Blog

Menu
  • Privacy Policy
  • Tech Sharing
  • animate sharing
  • Science Sharing
  • Happening
Menu

Eliem is the latest biotech company to go public in the Seattle area, raising US$80 million to help treat neurological diseases

Posted on August 10, 2021 by William
Bob Azabi. (Elim photo)

Eliem Therapeutics Joined the ranks of listed companies in Washington State, priced 6.4 million shares at US$12.50 and raised US$80 million. It initially planned to sell 4.5 million shares for $17 to $19.

Eliem will be traded on Nasdaq under the ticker symbol ELYM.

This Redmond, Washington-based start-up company was founded nearly three years ago and was led by a former Juno Therapeutics executive Bob Azabi — It is the latest biotechnology company to go public in Washington State​​. In the past 12 months, eight other biotech companies in the state have set prices for IPOs or went public through SPACs.

Eliem is still in the early stages of development, targeting its technology in areas such as chronic pain, psychiatry, epilepsy and other diseases related to the central nervous system.

It has not yet generated any product revenue and has accumulated losses of US$46.7 million as of March 31.

This is not uncommon for biotech companies, some of which take 10 years or more to develop a marketable drug.

Even so, Elim is still a small person. At the end of last year, it only hired 9 employees and reported no physical office space. The company raised two rounds of venture capital earlier this year, totaling $140 million, including $60 million in May.

The foundation of the company’s technology comes from two acquisitions. In February 2019, Eliem acquired NeoKera and eight months later acquired Athenen Therapeutics. Its main drug candidate is being developed for the treatment of diabetic peripheral neuropathic pain and pain associated with sciatica. Other drugs under development include potential treatments for major depression, perimenopausal depression, and focal seizures (the most common type of seizures in patients with epilepsy).

The company wrote: “Our product candidates focus on solving neuronal excitability disorders in large, well-defined markets where clinical and regulatory endpoints have been clearly established, and there are precedents for development pathways, but the current ​​​​The therapy poses challenges to patients in terms of efficacy, safety or tolerability,” the company wrote. In its SEC filing.

Recent Posts

  • F5 About 100 jobs will be cut due to the “current macroeconomic environment”
  • Neoriver decoration lights up Christmas
  • Naveen Jain’s microbiome and diagnostics startup Viome is raising more money
  • Cutting the wearable display in half is more difficult and easier than it looks
  • Oculus Studios acquired Camouflaj, a Seattle regional studio behind “Iron Man VR”
©2023 Lariva Business | Design: Newspaperly WordPress Theme